We then aimed to expand the scope by examining associations between circulating AVP (and its surrogate marker copeptin) and a range of metabolic disorders, including the relationship between AVP and metabolic dysfunction-associated steatotic liver disease (MASLD) and AVP and cardiovascular health. This evidence concerns the gene AVP and metabolic dysfunction-associated steatotic liver disease.